We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




New AI-System Detects Breast Cancer with Almost 100% Accuracy

By LabMedica International staff writers
Posted on 27 Jun 2024
Print article
Image: The new AI system can help with breast cancer diagnoses (Photo courtesy of David Litman/Shutterstock)
Image: The new AI system can help with breast cancer diagnoses (Photo courtesy of David Litman/Shutterstock)

Breast cancer represents 30% of all new cancer diagnoses in women annually, with projections from the American Cancer Society indicating that 42,500 women will succumb to the disease in 2024. Researchers have now developed a new artificial intelligence (AI) architecture capable of detecting breast cancer with a remarkable 99.72% accuracy, demonstrating the potential to redefine digital pathology.

This development follows a previous initiative by the same research team at Northeastern University (Boston, MA, USA) which launched a web-based AI application aimed at diagnosing prostate cancer more efficiently and accurately. These projects are part of a broader effort to establish an online platform that allows physicians to utilize advanced AI techniques for diagnosing various cancers. For the breast cancer project, the research team utilized the publicly accessible Breast Cancer Histopathological Database, which includes images of both malignant and benign breast tissues. Leveraging this resource, they built an ensemble deep learning model that integrates multiple models to enhance diagnostic precision and minimize errors, training it on the provided breast tissue imagery.

The AI system analyzes high-resolution images to identify cancerous patterns, learning from historical data to refine its diagnostic capabilities. This AI model is designed not to overlook any tumors in biopsies and maintains its efficacy regardless of the number of analyses performed. The goal is for this technology to not only expedite and improve patient treatment but also aid in the development of new AI models. These models could potentially diagnose rare and less common cancers, which traditionally suffer from a lack of available patient data.

“It’s like taking the diagnosis of multiple doctors and you vote to pick the best decision,” said Saeed Amal, Northeastern research professor of bioengineering who led the research team.

Related Links:
Northeastern University
Breast Cancer Histopathological Database

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)

First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring

Metabolic disorders such as diabetes and osteoporosis are rapidly increasing globally, especially in developing countries. Diagnosing these conditions generally requires blood tests; however, in remote... Read more

Molecular Diagnostics

view channel
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)

First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. While some individuals may experience a short-term illness, over half... Read more

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.